[{"id":"a7d87c22-61ed-4880-930a-7f94876963f9","acronym":"KEYNOTE-E64","url":"https://clinicaltrials.gov/study/NCT04787042","created_at":"2021-03-08T12:53:50.679Z","updated_at":"2025-02-25T16:11:14.799Z","phase":"Phase 1/2","brief_title":"Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067","source_id_and_acronym":"NCT04787042 - KEYNOTE-E64","lead_sponsor":"Simcha IL-18, Inc.","biomarkers":" ALK • TMB • MSI","pipe":" | ","alterations":" TMB-H • MSI-H/dMMR • ALK positive • ALK mutation","tags":["ALK • TMB • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H • MSI-H/dMMR • ALK positive • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Gazyva (obinutuzumab) • vevoctadekin (ST-067)"],"overall_status":"Recruiting","enrollment":" Enrollment 316","initiation":"Initiation: 08/06/2021","start_date":" 08/06/2021","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-11-15"}]